Several studies report that PLK4 expression positively correlates with various worse clinical outcomes and clinicopathological parameters, such as higher incidence of lymph node and distant metastases and poorer OS, progression-free survival (PFS) and RFS in breast cancer patients [37, 108, 109, 111]. This evidence concerns the gene PLK4 and breast carcinoma.